Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Shield Therapeutics ( (GB:STX) ) has issued an update.
Shield Therapeutics has confirmed that its issued share capital comprises 1,068,418,471 ordinary shares with equal voting rights and no shares held in treasury. This updated share count provides investors with the reference figure needed to assess and disclose their holdings under UK transparency rules, reinforcing clarity around the company’s capital structure while it continues to commercialise its ferric maltol franchise globally.
The group’s core product ACCRUFeR/FeRACCRU remains the first and only FDA-approved oral iron therapy for iron deficiency and iron deficiency anemia, now positioned as the leading branded prescription oral iron in the U.S. market. With patent protection extending into the mid-2030s and a network of regional partners commercialising the drug worldwide, Shield is seeking to strengthen its competitive position in a $2.3 billion market opportunity for iron deficiency treatments.
The most recent analyst rating on (GB:STX) stock is a Sell with a £9.50 price target. To see the full list of analyst forecasts on Shield Therapeutics stock, see the GB:STX Stock Forecast page.
Spark’s Take on STX Stock
According to Spark, TipRanks’ AI Analyst, STX is a Neutral.
The overall stock score is primarily influenced by the company’s robust technical momentum and positive corporate events, which are offset by significant financial challenges and valuation concerns. The strong technical indicators and strategic corporate developments provide optimism, but financial instability remains a critical risk.
To see Spark’s full report on STX stock, click here.
More about Shield Therapeutics
Shield Therapeutics is a commercial-stage specialty pharmaceutical group focused on treating iron deficiency and iron deficiency anemia with its lead oral iron therapy ACCRUFeR/FeRACCRU (ferric maltol). The company targets a sizeable U.S. and global market through a U.S. collaboration with Viatris and multiple licensing partners across Europe, Canada and Asia-Pacific.
Average Trading Volume: 1,903,149
Technical Sentiment Signal: Hold
Current Market Cap: £85.47M
Find detailed analytics on STX stock on TipRanks’ Stock Analysis page.